Avis Hans J, Vissers Maud N, Wijburg Frits A, Kastelein John J P, Hutten Barbara A
University of Amsterdam, Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Meibergdreef 9, Amsterdam, the Netherlands.
Curr Opin Investig Drugs. 2009 Mar;10(3):224-31.
Atherosclerosis, the condition underlying cardiovascular disease (CVD), often begins in childhood. Therefore, strategies to prevent CVD should be implemented at an early age, especially in populations at high risk for CVD. In addition to lifestyle interventions, these strategies include pharmacological treatment of dyslipidemia, a well-established risk factor for CVD in adults. Several lipid-lowering agents have been evaluated in children; however, long-term safety and efficacy data are lacking. As in adults, statins are the preferred pharmacological agents in pediatric practice due to excellent efficacy and tolerability, with few adverse safety outcomes observed to date. Nevertheless, more studies are needed to confirm the lifelong benefit of lipid-lowering therapy initiated in childhood.
动脉粥样硬化是心血管疾病（CVD）的潜在病因，通常始于童年时期。因此，预防心血管疾病的策略应在早年实施，尤其是在心血管疾病高危人群中。除生活方式干预外，这些策略还包括对血脂异常进行药物治疗，血脂异常是成人心血管疾病中公认的危险因素。已经对几种降脂药物在儿童中进行了评估；然而，缺乏长期安全性和有效性数据。与成人一样，他汀类药物由于疗效优异且耐受性良好，是儿科实践中首选的药物，迄今为止观察到的不良安全结果很少。尽管如此，仍需要更多研究来证实儿童期开始的降脂治疗的终身益处。
